EWP
CYTK icon

Elevation Wealth Partners’s Cytokinetics CYTK Stock Holding History

Elevation Wealth Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.88K Hold
74
– – ﹤0.01% 1109
2026
Q2 		$6.3K Buy
+74
New +$5.31K ﹤0.01% 953
2026
Q1 		– Sell
-65
Closed -$4.13K – 1091
2025
Q4 		$4.13K Buy
+65
New +$4.04K ﹤0.01% 671

Other funds holding CYTK

MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

Elevation Wealth Partners's CYTK Position: Q3 2026 in Review

Elevation Wealth Partners held its Cytokinetics (CYTK) position steady in Q3 2026 at 74 shares worth $4.88K. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

Elevation Wealth Partners first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.3K in Q2 2026. 10 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • Elevation Wealth Partners held 74 shares of Cytokinetics worth $4.88K as of Q3 2026.
  • Elevation Wealth Partners left its Cytokinetics share count unchanged in Q3 2026.
  • Cytokinetics made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #1109 holding.
  • Elevation Wealth Partners first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • Elevation Wealth Partners's Cytokinetics position peaked at $6.3K in Q2 2026.
  • 10 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.